EP1551383A4 - VERFAHRN ZUR PRûVENTION UND BEHANDLUNG VON MIKROBIELLEN INFEKTIONEN DURCH MODULIERUNG VON TRANSKRIPTIONSFAKTOREN - Google Patents

VERFAHRN ZUR PRûVENTION UND BEHANDLUNG VON MIKROBIELLEN INFEKTIONEN DURCH MODULIERUNG VON TRANSKRIPTIONSFAKTOREN

Info

Publication number
EP1551383A4
EP1551383A4 EP03742158A EP03742158A EP1551383A4 EP 1551383 A4 EP1551383 A4 EP 1551383A4 EP 03742158 A EP03742158 A EP 03742158A EP 03742158 A EP03742158 A EP 03742158A EP 1551383 A4 EP1551383 A4 EP 1551383A4
Authority
EP
European Patent Office
Prior art keywords
preventing
methods
transcription factors
microbial infections
treating microbial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03742158A
Other languages
English (en)
French (fr)
Other versions
EP1551383A2 (de
Inventor
Michael N Alekshun
Stuart B Levy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Paratek Pharmaceuticals Inc
Original Assignee
Paratek Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharmaceuticals Inc filed Critical Paratek Pharmaceuticals Inc
Priority to EP12158058.3A priority Critical patent/EP2586440A2/de
Publication of EP1551383A2 publication Critical patent/EP1551383A2/de
Publication of EP1551383A4 publication Critical patent/EP1551383A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
EP03742158A 2002-06-24 2003-06-24 VERFAHRN ZUR PRûVENTION UND BEHANDLUNG VON MIKROBIELLEN INFEKTIONEN DURCH MODULIERUNG VON TRANSKRIPTIONSFAKTOREN Withdrawn EP1551383A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12158058.3A EP2586440A2 (de) 2002-06-24 2003-06-24 Verfahren zur Vorbeugung und Behandlung von mikrobiellen Infektionen durch Modulation von Transkriptionsfaktoren

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US39134502P 2002-06-24 2002-06-24
US391345P 2002-06-24
US42121802P 2002-10-25 2002-10-25
US421218P 2002-10-25
US42914202P 2002-11-26 2002-11-26
US429142P 2002-11-26
US45893503P 2003-03-31 2003-03-31
US458935P 2003-03-31
PCT/US2003/019831 WO2004000228A2 (en) 2002-06-24 2003-06-24 Methods for preventing and treating microbial infections by modulating transcription factors

Publications (2)

Publication Number Publication Date
EP1551383A2 EP1551383A2 (de) 2005-07-13
EP1551383A4 true EP1551383A4 (de) 2007-12-05

Family

ID=30003984

Family Applications (2)

Application Number Title Priority Date Filing Date
EP03742158A Withdrawn EP1551383A4 (de) 2002-06-24 2003-06-24 VERFAHRN ZUR PRûVENTION UND BEHANDLUNG VON MIKROBIELLEN INFEKTIONEN DURCH MODULIERUNG VON TRANSKRIPTIONSFAKTOREN
EP12158058.3A Withdrawn EP2586440A2 (de) 2002-06-24 2003-06-24 Verfahren zur Vorbeugung und Behandlung von mikrobiellen Infektionen durch Modulation von Transkriptionsfaktoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP12158058.3A Withdrawn EP2586440A2 (de) 2002-06-24 2003-06-24 Verfahren zur Vorbeugung und Behandlung von mikrobiellen Infektionen durch Modulation von Transkriptionsfaktoren

Country Status (5)

Country Link
EP (2) EP1551383A4 (de)
JP (3) JP2006504677A (de)
AU (2) AU2003279273B2 (de)
CA (1) CA2489943A1 (de)
WO (1) WO2004000228A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120303289A1 (en) * 2009-12-02 2012-11-29 Anders Ohrn Combined on-lattice/off-lattice optimization method for rigid body docking
WO2014059313A1 (en) * 2012-10-12 2014-04-17 Lehigh University Thermally stable enzymes, compositions thereof and methods of using same
CN111166743B (zh) * 2020-01-02 2022-03-22 中国医学科学院医药生物技术研究所 一类含噻唑结构化合物的抗感染用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3830697A1 (de) * 1988-09-09 1990-03-22 Knoll Ag Substituierte phenylacetonitrile zur verwendung als resistenzbrecher
JPH0826991A (ja) * 1994-07-14 1996-01-30 Kureha Chem Ind Co Ltd 抗生物質耐性微生物の薬剤感受性増感剤
WO1998006837A1 (en) * 1996-08-16 1998-02-19 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
WO1998037188A1 (en) * 1997-02-21 1998-08-27 Hybridon, Inc. OLIGONUCLEOTIDES SPECIFIC FOR THE marORAB OPERON
US5817793A (en) * 1992-08-28 1998-10-06 Trustees Of Tufts College Multiple antibiotic resistance operon assays
WO2000052144A1 (en) * 1999-03-03 2000-09-08 Board Of Regents, The University Of Texas System Genetic and epigenetic manipulation of abc transporters and ecto-phosphatases for the conference of drug resistance and for the loss of drug resistance in biological systems and methods for the detection of ecto-phosphatase inhibitors
WO2004001058A2 (en) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4745056A (en) 1984-10-23 1988-05-17 Biotechnica International, Inc. Streptomyces secretion vector
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4820639A (en) 1985-12-04 1989-04-11 Massachusetts Institute Of Technology Process for enhancing translational efficiency of eukaryotic mRNA
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5292646A (en) 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
US5563036A (en) * 1994-04-29 1996-10-08 Tularik, Inc. Transcription factor-DNA binding assay
ATE211506T1 (de) 1995-01-31 2002-01-15 Bioimage As Ein verfahren zum nachweis biologisch aktiver substanzen
US5679364A (en) 1995-06-07 1997-10-21 Lee County Mosquito Control District Compositions and methods for reducing the amount of contaminants in aquatic and terrestrial environments
US6057367A (en) * 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
EP1080232A2 (de) * 1998-05-22 2001-03-07 Tufts University Helix-turn-helix domänen der mara familie und methoden zu deren verwendung

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3830697A1 (de) * 1988-09-09 1990-03-22 Knoll Ag Substituierte phenylacetonitrile zur verwendung als resistenzbrecher
US5817793A (en) * 1992-08-28 1998-10-06 Trustees Of Tufts College Multiple antibiotic resistance operon assays
JPH0826991A (ja) * 1994-07-14 1996-01-30 Kureha Chem Ind Co Ltd 抗生物質耐性微生物の薬剤感受性増感剤
WO1998006837A1 (en) * 1996-08-16 1998-02-19 Yale University Phenotypic conversion of drug-resistant bacteria to drug-sensitivity
WO1998037188A1 (en) * 1997-02-21 1998-08-27 Hybridon, Inc. OLIGONUCLEOTIDES SPECIFIC FOR THE marORAB OPERON
WO2000052144A1 (en) * 1999-03-03 2000-09-08 Board Of Regents, The University Of Texas System Genetic and epigenetic manipulation of abc transporters and ecto-phosphatases for the conference of drug resistance and for the loss of drug resistance in biological systems and methods for the detection of ecto-phosphatase inhibitors
WO2004001058A2 (en) * 2001-05-04 2003-12-31 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof

Also Published As

Publication number Publication date
CA2489943A1 (en) 2003-12-31
WO2004000228A3 (en) 2004-10-28
EP2586440A2 (de) 2013-05-01
JP2006504677A (ja) 2006-02-09
JP2012214493A (ja) 2012-11-08
AU2009213078B2 (en) 2012-01-19
AU2003279273B2 (en) 2009-10-01
JP2009280591A (ja) 2009-12-03
AU2009213078C1 (en) 2013-01-17
WO2004000228A2 (en) 2003-12-31
AU2003279273A1 (en) 2004-01-06
AU2009213078A1 (en) 2009-10-08
EP1551383A2 (de) 2005-07-13

Similar Documents

Publication Publication Date Title
AU2003300773A1 (en) Improved apparatus and method for cryosurgery
AU2003259925A1 (en) Well treatment apparatus and method
AU2003248837A1 (en) Methods and devices for treating aneurysms
AU2003287210A1 (en) Method for treating emissions
AU2003263040A1 (en) Method and apparatus for multi-level security implementation
AU2003299561A1 (en) Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
GB2425617B (en) Device for preventing and treating myopia
AU2003232044A1 (en) Composition and method for dermatological treatment
AU2003296968A1 (en) Method and apparatus for preventing and treating eyelid problems
AU2003249181A1 (en) Methods for treating or preventing ischemic injury
AU2003217832A1 (en) Catheter for treating vulnerable plaque
AU2003239132A8 (en) Methods and compositions for preventing and treating microbial infections
AU2003256526A1 (en) Arrangements and methods for treating a subject
AU2003222022A1 (en) Methods for treating deodorizer distillate
AU2003296963A1 (en) Methods and compositions for treating and preventing ear infections
IL177680A0 (en) System and method for adaptive modulation
AU2002353774A1 (en) Products and methods for treating microbial infections
AU2003278657A1 (en) Method and apparatus for water treatment
AU2003292231A1 (en) Methods for diagnosing and treating schizophrenia
AU2003259202A1 (en) Compositions and methods for treating and preventing infection
AU2003262840A1 (en) Composition and method for treating skin
WO2004071432A3 (en) Method for treating hypothyroidism
AU2003290506A1 (en) Methods and devices for treating severe peripheral bacterial infections
AU2003239455A1 (en) Method for treating dermatoses and tissue damage
AU2003260753A1 (en) Inoculation method and related apparatus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050117

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20071107

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/555 20060101ALI20071031BHEP

Ipc: A61K 31/54 20060101ALI20071031BHEP

Ipc: A61K 31/41 20060101ALI20071031BHEP

Ipc: A61K 31/38 20060101ALI20071031BHEP

Ipc: A61K 31/35 20060101ALI20071031BHEP

Ipc: A61K 31/34 20060101ALI20071031BHEP

Ipc: A61K 31/33 20060101AFI20071031BHEP

17Q First examination report despatched

Effective date: 20100224

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140103